Key considerations in assessing relapse
| . | Element . | Considerations . |
|---|---|---|
| Patient | Frailty | Fit, intermediate, frail |
| Comorbidities and prior toxicities | Cardiovascular disease, neuropathy, and cytopenias to prior therapy are particularly important to recognize | |
| Practical limitations | Travel, cost, cognitive impairment, caregiver support | |
| Disease | Risk | FISH, karyotype |
| Change in phenotype | Plasma cell leukemia, extramedullary disease, amyloidosis | |
| Dynamics of relapse | Slow vs rapid, serologic vs symptoms | |
| Refractoriness | Single, dual, or more |
| . | Element . | Considerations . |
|---|---|---|
| Patient | Frailty | Fit, intermediate, frail |
| Comorbidities and prior toxicities | Cardiovascular disease, neuropathy, and cytopenias to prior therapy are particularly important to recognize | |
| Practical limitations | Travel, cost, cognitive impairment, caregiver support | |
| Disease | Risk | FISH, karyotype |
| Change in phenotype | Plasma cell leukemia, extramedullary disease, amyloidosis | |
| Dynamics of relapse | Slow vs rapid, serologic vs symptoms | |
| Refractoriness | Single, dual, or more |